TD Cowen analyst Dan Brennan lowered the firm’s price target on Exact Sciences to $100 from $120 and keeps an Outperform rating on the shares. The firm said Exact Sciences is differentiated among peers given its rapidly rising margins and its Q3 results supports their thesis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EXAS:
- Exact Sciences sees FY23 revenue $2.476B-$2.486B, consensus $2.46B
- Exact Sciences reports Q3 EPS 0c, consensus (49c)
- Exact Sciences Announces Third-Quarter 2023 Results
- Notable companies reporting after market close
- ‘Buy the Dip’: Analysts Say These 2 Beaten-Down Stocks Offer a Compelling Entry Point — Here’s Why They Could Rebound